» INDUSTRY NEWS
» Baxter BioPharma Solutions Joins PBOA
Nelson Patterson Elected to Board as Outsourcing Association Welcomes Top-Tier CDMO
The Pharma & Biopharma Outsourcing Association (PBOA) announced that Nelson Patterson, Vice President, Sales and Marketing at Baxter BioPharma Solutions, has been elected to its Board of Trustees, eff ective immediately. Mr. Patterson was elected after Baxter BioPharma Solutions joined the PBOA as a Sustaining Member.
“We are very pleased to have Nelson join the PBOA Board of Trustees and to have Baxter BioPharma Solutions as the newest member of our association,” said Gil Roth, President of the Pharma & Biopharma Outsourcing Association. “His extensive experience will be an asset to our Board, as we pursue our goal of strengthening the CMO/CDMO sector. The addition of Baxter to our core membership will also help us advance our agenda and better enable us to illustrate the importance of outsourcing partnerships to the healthcare ecosystem."
“As a strong advocate for our industry, PBOA plays an important and collaborative role in educating multiple parties about what we do to develop and manufacture pharma and biopharma products for healthcare providers, caregivers and, most importantly, patients,” said Baxter’s Mr. Patterson. “Baxter has a deep-seated commitment to saving and sustaining lives worldwide, so I am excited at the opportunity to work with peers and PBOA leadership to advance our common goal of making a meaningful diff erence in the lives of patients.”
“I am thrilled to have Nelson join our Board of Trustees,” added Peter T. Bigelow, Chairman of the Board at PBOA. “He brings an understanding of partnering in the biopharmaceutical sector, and I am confi dent that he will contribute in a variety of ways as the PBOA advances its members' strategic goals and objectives.”
Nelson Patterson has global responsibility for Baxter’s BioPharma Solutions pharmaceutical partnering business, leading both marketing and sales. With experience at both small start-ups and global Fortune 500 fi rms, he brings over 25 years of experience in consumer marketing, pharmaceutical and medical device development and launch, and manufacturing facility management. Nelson holds a degree in Economics and Spanish from Washington & Lee University, and a Master's in Business Administration from The Darden School at the University of Virginia.
Media Coverage of Political Disputes About Vaccines and Other Public Health Measures Can Do Harm
As clashing politicians appear in media stories about vaccines, a new study shows that coverage of these controversies stokes partisanship and undermines faith in life-saving advice from doctors and public officials.
68 | | January/February 2015
Researchers released a new Scholars Strategy Network brief summarizing major fi ndings on 2 recent, widely publicized cases of political disputes about public health questions.
The researchers, Erika Franklin Fowler, an Associate Professor of Government at Wesleyan University, and Sarah Elizabeth Gollust, an Assistant Professor of Public Health in the Division of Health Policy and Management at the University of Minnesota School of Public Health, examined the 2009 dust-up over mammography screenings and the 2006-07 fi ghts over whether middle-school girls should be required to be vaccinated against infections by the human papilloma virus. This research draws on experimental results along with evidence about trends in media coverage, with results fully reported in a just-released March 2015 article in the Annals of the American Academy of Political and Social Science.
In the researchers' experiments, according to their brief, "Participants who were newly exposed to stories about political confl icts concerning human papillomavirus vaccination became less supportive of vaccines in general—suggesting that something similar could fl ow from current media coverage of political arguments about measles vaccination. In addition, higher levels of media coverage of political confl ict were associated with lower trust in government and doctors."
Fowler and Gollust wrote, "Vaccines only work to prevent dread
diseases when almost everyone is vaccinated. Our research on news
publicity about political disputes suggests that American
society could be on a slippery slope toward distrust of public health recommendations and unwillingness to accept vaccination, with potentially concerning consequences not just for convinced hard-core opponents but everyone."
Hemispherx Biopharma Posts USAMRIID Ebola Study Concluding Ampligen® Produced 100% Survival Rate in Rodents with 100% mortality in the placebo
Hemispherx Challenges False Accusations in Recent Online and Social Media Postings
Based upon numerous Hemispherx stockholder requests, Hemispherx Biopharma, Inc. (the “Company” or “Hemispherx”) has posted the report and fi ndings of the recent effi cacy study of Ampligen® in a mouse model of Ebola virus infection performed by scientists at the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID). The posted USAMRIID report conclusively refutes false and defamatory blog and online statements by
TheStreet.com’s
blogger Adam
Feuerstein and invalidates Feuerstein’s negative social media postings about the company’s press release that was issued on February 2, 2015.
As requested by stockholders, the USAMRIID report can now be viewed in its entirety on the company’s website:
www.hemispherx.net.
“Anyone who reads the USAMRIID report can see Feuerstein is wrong. This is blatant short mongering at its worst,” said Thomas K. Equels, Hemispherx’ Executive Vice Chairman.
“Feuerstein’s defamation of
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76